

Free grant of redeemable equity warrants to shareholders: Increase of the number of warrants

PARIS and BOULDER (CO), June 4, 2021 – 17:45 CEST - **SpineGuard** (FR0011464452 – ALSGD), an innovative company that deploys its DSG[®] (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announced today that pursuant to the issue of 300,864 new shares deriving from the equity line with Nice & Green, the total number of shares of SpineGuard increased to 26,851,357.

As a result, the Board of Directors resolved on the corresponding adjustment to the common stock on June 3, 2021 impacting the total number of redeemable equity warrants (BSAR) to be issued under the free grant of BSAR announced last June 2, 2021.

Per the delegation of authority by the Board of Directors, at its May 27, 2021 meeting, the CEO resolved on June 3, 2021 on the issue and the free allocation to all shareholders of 26,851,357 BSAR (vs. 26,550,493 BSAR previously).

In the event of the exercising of all the BSAR, a maximum of 2,983,484 new shares (vs. 2,950,054 previously) corresponding to a total gross equity funding of € 5,370,271.20 (vs. € 5,310,597.20 previously).

All the other terms of the free grant of BSAR remain unchanged.

About SpineGuard[®]

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG[®] (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 80,000 surgical procedures worldwide. Seventeen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG[®] offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG[®] was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard

Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

NewCap

Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tel.: +33 1 44 71 94 94
spineguard@newcap.eu

SpineGuard

Manuel Lanfossi
CFO
Tel: +33 1 45 18 45 19
m.lanfossi@spineguard.com

